Hepatitis C virus infection in patients with primary biliary cirrhosis

Hsuan-Wei Chen; Hsin-Hung Huang; Ching-Huang Lai; Wei-En Chang; Yu-Lueng Shih; Wei-Kuo Chang; Tsai-Yuan Hsieh; Heng-Cheng Chu

Hepatitis C virus infection in patients with primary biliary cirrhosis

Hsuan-Wei Chen, Hsin-Hung Huang, Ching-Huang Lai, Wei-En Chang, Yu-Lueng Shih, Wei-Kuo Chang, Tsai-Yuan Hsieh, Heng-Cheng Chu

Research output: Contribution to journal › Article › peer-review

10 Citations (Scopus)

Abstract

Background and aim. The aim of this study is to evaluate the role of hepatitis C virus (HCV) infection in patients with primary biliary cirrhosis (PBC). Material and methods. On the basis of a retrospective review of medical records, all patients consecutively diagnosed with PBC or HCV infection between 1999 and 2011 and who had a regular follow-up of at least 3 years were included in the study. Clinical characteristics, especially the severity of cirrhosis, were analyzed in PBC patients with HCV infection (PBC-HCV), PBC patients without HCV infection (PBC-only), and patients with only HCV infection (HCV-only). Results. A total of 76 patients with PBC, including 9 patients with HCV infection, were analyzed. Of the PBC-HCV patients, 7 (7/9, 77.8%) were women with a mean age of 55.11 ± 14.29 years. Age- and sex-matched PBC-only patients (n = 36) and HCV-only patients (n = 36) were used as control groups. In comparison to the PBC-only controls, PBC-HCV patients had a greater severity of cirrhosis based on Child-Pugh (p = 0.019) and Model for End-Stage Liver Disease (MELD) (p = 0.01) scores. However, no significant difference in the severity of cirrhosis was found between the PBC-HCV and HCV-only control patients (p = 0.94 in Child-Pugh scores; p = 0.64 in MELD scores). Conclusions. In PBC patients with concomitant HCV infection, aggressive management may be warranted in view of the associated more severe liver cirrhosis.

Original language	English
Pages (from-to)	78-84
Number of pages	7
Journal	Annals of Hepatology
Volume	12
Issue number	1
Publication status	Published - 2013
Externally published	Yes

Keywords

Child-Pugh score
Cirrhosis
MELD score
alanine aminotransferase
albumin
aspartate aminotransferase
bilirubin
creatinine
interferon
ribavirin
virus RNA
adult
age
aged
article
ascites
autoimmune disease
bleeding
Child Pugh score
clinical article
comorbidity
controlled study
death
disease severity
female
follow up
hepatitis C
human
international normalized ratio
liver cell carcinoma
liver cirrhosis
male
medical record review
Model For End Stage Liver Disease Score
neoplasm
primary biliary cirrhosis
survival rate
virus load
biliary cirrhosis
case control study
disease course
middle aged
prognosis
retrospective study
severity of illness index
Adult
Aged
Case-Control Studies
Disease Progression
Female
Hepatitis C
Humans
Liver Cirrhosis, Biliary
Male
Middle Aged
Prognosis
Retrospective Studies
Severity of Illness Index

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

http://www.scopus.com/inward/record.url?eid=2-s2.0-84878749370&partnerID=40&md5=1479c64ff438c1c6df597561fb0ba94a

Cite this

@article{95c81ec7c1d54c7f93e128daecea7310,

title = "Hepatitis C virus infection in patients with primary biliary cirrhosis",

abstract = "Background and aim. The aim of this study is to evaluate the role of hepatitis C virus (HCV) infection in patients with primary biliary cirrhosis (PBC). Material and methods. On the basis of a retrospective review of medical records, all patients consecutively diagnosed with PBC or HCV infection between 1999 and 2011 and who had a regular follow-up of at least 3 years were included in the study. Clinical characteristics, especially the severity of cirrhosis, were analyzed in PBC patients with HCV infection (PBC-HCV), PBC patients without HCV infection (PBC-only), and patients with only HCV infection (HCV-only). Results. A total of 76 patients with PBC, including 9 patients with HCV infection, were analyzed. Of the PBC-HCV patients, 7 (7/9, 77.8%) were women with a mean age of 55.11 ± 14.29 years. Age- and sex-matched PBC-only patients (n = 36) and HCV-only patients (n = 36) were used as control groups. In comparison to the PBC-only controls, PBC-HCV patients had a greater severity of cirrhosis based on Child-Pugh (p = 0.019) and Model for End-Stage Liver Disease (MELD) (p = 0.01) scores. However, no significant difference in the severity of cirrhosis was found between the PBC-HCV and HCV-only control patients (p = 0.94 in Child-Pugh scores; p = 0.64 in MELD scores). Conclusions. In PBC patients with concomitant HCV infection, aggressive management may be warranted in view of the associated more severe liver cirrhosis.",

keywords = "Child-Pugh score, Cirrhosis, MELD score, alanine aminotransferase, albumin, aspartate aminotransferase, bilirubin, creatinine, interferon, ribavirin, virus RNA, adult, age, aged, article, ascites, autoimmune disease, bleeding, Child Pugh score, clinical article, comorbidity, controlled study, death, disease severity, female, follow up, hepatitis C, human, international normalized ratio, liver cell carcinoma, liver cirrhosis, male, medical record review, Model For End Stage Liver Disease Score, neoplasm, primary biliary cirrhosis, survival rate, virus load, biliary cirrhosis, case control study, disease course, middle aged, prognosis, retrospective study, severity of illness index, Adult, Aged, Case-Control Studies, Disease Progression, Female, Hepatitis C, Humans, Liver Cirrhosis, Biliary, Male, Middle Aged, Prognosis, Retrospective Studies, Severity of Illness Index",

author = "Hsuan-Wei Chen and Hsin-Hung Huang and Ching-Huang Lai and Wei-En Chang and Yu-Lueng Shih and Wei-Kuo Chang and Tsai-Yuan Hsieh and Heng-Cheng Chu",

note = "被引用次數：1 Export Date: 22 March 2016 通訊地址: Chu, H.-C.; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center No. 325, Section 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan; 電子郵件： [email protected] 化學物質/CAS: alanine aminotransferase, 9000-86-6, 9014-30-6; aspartate aminotransferase, 9000-97-9; bilirubin, 18422-02-1, 635-65-4; creatinine, 19230-81-0, 60-27-5; ribavirin, 36791-04-5 出資詳情: NSC94-2314-B-016-047, National Science Council Taiwan 參考文獻: Kaplan, M.M., Gershwin, M.E., Primary biliary cirrhosis (2006) N Engl J Med, 353, pp. 1261-1273; Myers, R.P., Shaheen, A.A., Fong, A., Burak, K.W., Wan, A., Swain, M.G., Hilsden, R.J., Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: A population-based study (2009) Hepatology, 50, p. 1884; Kumagi, T., Heathcote, E.J., Primary biliary cirrhosis (2008) Orphanet J Rare Dis, 3, p. 1; Poupon, R.E., Lindor, K.D., Par{\'e}s, A., Chazouilleres, O., Poupon, R., Heathcote, E.J., Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis (2003) J Hepatol, 39, pp. 12-16; Davis, G.L., Albright, J.E., Cook, S.F., Rosenberg, D.M., Projecting future complications of chronic hepatitis C in the United-States (2003) Liver Transpl, 9, pp. 331-338; Haddad, J., Deny, P., Munz-Gotheil, C., Ambrosini, J.C., Trinchet, J.C., Pateron, D., Mal, F., Lymphocytic sialadenitis of Sj{\"o}gren's syndrome associated with chronic hepatitis C virus liver disease (1992) Lancet, 339, pp. 321-323; Marcellin, P., Pouteau, M., Benhamou, J.P., Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction (1995) J Hepatol, 22, pp. 364-369; Lunel, F., Cacoub, P., Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection (1999) J Hepatol, 31, pp. 210-216; Floreani, A., Baragiotta, A., Leone, M.G., Baldo, V., Naccarato, R., Primary biliary cirrhosis and hepatitis C virus infection (2003) Am J Gastroenterol, 98, pp. 2757-2762; Wiesner, R., Edwards, E., Freeman, R., Harper, A., Kim, R., Kamath, P., Kremers, W., Model for end-stage liver disease (MELD) and allocation of donor livers (2003) Gastroenterology, 124, pp. 91-96; Housset, C., Hirschauer, C., Degos, F., False positive anti-HCV in biliary cirrhosis (1991) Lancet, 114, p. 252. , (Letter); Fusconi, M., Lenzi, M., Ballardini, G., Miniero, R., Cassani, F., Zauli, D., Bianchi, F.B., Anti-HCV testing in autoimmune hepatitis and primary biliary cirrhosis (1990) Lancet, 336, p. 823; Imada, J., Hoshino, H., Nishimura, D., Morita, K., Yoshida, N., Katada, N., Sano, H., Case report: Multiple cancers: Hepatocellular carcinoma and adenocarcinomas of the common bile duct and the gall-bladder in a woman with primary biliary cirrhosis (1996) J Gastroenterol Hepatol, 11, pp. 546-550; Hoso, M., Nakanuma, Y., Kawano, M., Oda, K., Tsuneyama, K., van de water, J., Gershiwin, M.E., Granulomatous cholangitis in chronic hepatitis C: A new diagnostic problem in liver pathology (1996) Pathol Int, 46, pp. 301-305; Mouelhi, L., Chaieb, M., Sfar, I., Debbeche, R., Trabelsi, S., Gorgi, Y., Najjar, T., Chronic viral C hepatitis associated with primary biliary cirrhosis. Report of two cases (2009) Rev Med Interne, 30, pp. 537-539; Ramos-Casals, M., Pares, A., Jara, L.J., Solans, R., Vi{\~n}as, O., V{\'a}zquez, P., S{\'a}nchez-Tapias, Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: Description of 18 cases and review of the literature (2005) J Viral Hepat, 12, pp. 648-654. , HISPAMEC Study Group; Sung, J.L., Prevention of hepatitis B and C virus infection for prevention of cirrhosis and hepatocellular carcinoma (1997) J Gastroenterol Hepatol, 12, pp. S370-S376; Wang, J.T., Wang, T.H., Sheu, J.C., Tsai, S.J., Hsieh, Y.S., Lin, D.T., Wang, C.Y., Hepatitis C virus infection in volunteer blood donors in Taiwan. Evaluation by hepatitis C antibody assays and the polymerase chain reaction (1993) Arch Pathol Lab Med, 117, pp. 152-156; Nakamura, M., Yasunami, M., Kondo, H., Horie, H., Aiba, Y., Komori, A., Migita, K., Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): The HLA-DRB1 polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC (2010) Hepatol Res, 40, pp. 494-504. , PBC Study Group in NHOSLJ; Gershwin, M.E., Selmi, C., Worman, H.J., Gold, E.B., Watnik, M., Utts, J., Lindor, K.D., Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview based study of 1032 patients (2005) Hepatology, 42, pp. 1194-1202; Ala, A., Stanca, C.M., Bu-Ghanim, M., Ahmado, I., Branch, A.D., Schiano, T.D., Odin, J.A., Increased prevalence of primary biliary cirrhosis near superfund toxic waste sites (2006) Hepatology, 43, pp. 525-531; Ishibashi, H., Komori, A., Shimoda, S., Ambrosini, Y.M., Gershwin, M.E., Nakamura, M., Risk factors and prediction of long-term outcome in primary biliary cirrhosis (2011) Intern Med, 50, pp. 1-10; Cavazza, A., Caballer{\'i}a, L., Floreani, A., Farinati, F., Bruguera, M., Caroli, D., Par{\'e}s, A., Incidence, Risk Factors, and Survival of Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Comparative Analysis from Two Centers (2009) Hepatology, 50, pp. 1162-1168; Macaron, C., Hanouneh, I.A., Zein, N.N., Incidence, Risk Factors, and Survival of Hepatocellular Carcinoma in Primary Biliary Cirrhosis (2010) Hepatology, 52, p. 2239. , author reply 2239-40; Michel, F., Toussirot, E., Wendling, D., Primary biliary cirrhosis and systemic lupus erythematosus. A new case report (1998) Rev Rhum Engl Ed, 65, pp. 504-507; Shizuma, T., Kuroda, H., A case of primary biliary cirrhosis which developed eight years after diagnosis of systemic lupus erythematosus (2011) Intern Med, 50, pp. 321-324; Watt, E.F., James, O.F., Jones, D.E., Patterns of autoimmunity in primary biliary cirrhosis patients and their families: A population-based cohort study (2004) QJM, 97, pp. 397-406; Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Gon{\c c}ales Jr., F.L., H{\"a}ussinger, D., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection (2002) N Engl J Med, 26, pp. 975-982; Yoshikawa, M., Mimura, M., Shiroi, A., Kojima, H., Fukui, H., Sugimoto, Y., Mochi, T., Primary biliary cirrhosis exacerbated by a course of acute hepatitis C and subsequent interferon therapy (2000) Am J Gastroenterol, 95, pp. 2396-2397; Maeda, T., Onishi, S., Miura, T., Iwamura, S., Tomita, A., Saibara, T., Yamamoto, Y., Exacerbation of primary biliary cirrhosis during interferon-alpha 2b therapy for chronic active hepatitis C (1995) Dig Dis Sci, 40, pp. 1226-1230; D'Amico, E., Paroli, M., Fratelli, V., Palazzi, C., Barnaba, V., Callea, F., Consoli, G., Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection (1995) Dig Dis Sci, 40, pp. 2113-2116; Lok, A.S., Gardiner, D.F., Lawitz, E., Martorell, C., Everson, G.T., Ghalib, R., Reindollar, R., Preliminary study of two antiviral agents for hepatitis C genotype 1 (2012) N Engl J Med, 366, pp. 216-224; Chung, R.T., A Watershed Moment in the Treatment of Hepatitis C (2012) N Engl J Med, 366, pp. 273-275",

year = "2013",

language = "English",

volume = "12",

pages = "78--84",

journal = "Annals of Hepatology",

issn = "1665-2681",

publisher = "Elsevier Espana S.L.U",

number = "1",

}

TY - JOUR

T1 - Hepatitis C virus infection in patients with primary biliary cirrhosis

AU - Chen, Hsuan-Wei

AU - Huang, Hsin-Hung

AU - Lai, Ching-Huang

AU - Chang, Wei-En

AU - Shih, Yu-Lueng

AU - Chang, Wei-Kuo

AU - Hsieh, Tsai-Yuan

AU - Chu, Heng-Cheng

N1 - 被引用次數：1 Export Date: 22 March 2016 通訊地址: Chu, H.-C.; Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center No. 325, Section 2, Cheng-Kung Road, Neihu 114, Taipei, Taiwan; 電子郵件： [email protected] 化學物質/CAS: alanine aminotransferase, 9000-86-6, 9014-30-6; aspartate aminotransferase, 9000-97-9; bilirubin, 18422-02-1, 635-65-4; creatinine, 19230-81-0, 60-27-5; ribavirin, 36791-04-5 出資詳情: NSC94-2314-B-016-047, National Science Council Taiwan 參考文獻: Kaplan, M.M., Gershwin, M.E., Primary biliary cirrhosis (2006) N Engl J Med, 353, pp. 1261-1273; Myers, R.P., Shaheen, A.A., Fong, A., Burak, K.W., Wan, A., Swain, M.G., Hilsden, R.J., Epidemiology and natural history of primary biliary cirrhosis in a Canadian health region: A population-based study (2009) Hepatology, 50, p. 1884; Kumagi, T., Heathcote, E.J., Primary biliary cirrhosis (2008) Orphanet J Rare Dis, 3, p. 1; Poupon, R.E., Lindor, K.D., Parés, A., Chazouilleres, O., Poupon, R., Heathcote, E.J., Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis (2003) J Hepatol, 39, pp. 12-16; Davis, G.L., Albright, J.E., Cook, S.F., Rosenberg, D.M., Projecting future complications of chronic hepatitis C in the United-States (2003) Liver Transpl, 9, pp. 331-338; Haddad, J., Deny, P., Munz-Gotheil, C., Ambrosini, J.C., Trinchet, J.C., Pateron, D., Mal, F., Lymphocytic sialadenitis of Sjögren's syndrome associated with chronic hepatitis C virus liver disease (1992) Lancet, 339, pp. 321-323; Marcellin, P., Pouteau, M., Benhamou, J.P., Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction (1995) J Hepatol, 22, pp. 364-369; Lunel, F., Cacoub, P., Treatment of autoimmune and extrahepatic manifestations of hepatitis C virus infection (1999) J Hepatol, 31, pp. 210-216; Floreani, A., Baragiotta, A., Leone, M.G., Baldo, V., Naccarato, R., Primary biliary cirrhosis and hepatitis C virus infection (2003) Am J Gastroenterol, 98, pp. 2757-2762; Wiesner, R., Edwards, E., Freeman, R., Harper, A., Kim, R., Kamath, P., Kremers, W., Model for end-stage liver disease (MELD) and allocation of donor livers (2003) Gastroenterology, 124, pp. 91-96; Housset, C., Hirschauer, C., Degos, F., False positive anti-HCV in biliary cirrhosis (1991) Lancet, 114, p. 252. , (Letter); Fusconi, M., Lenzi, M., Ballardini, G., Miniero, R., Cassani, F., Zauli, D., Bianchi, F.B., Anti-HCV testing in autoimmune hepatitis and primary biliary cirrhosis (1990) Lancet, 336, p. 823; Imada, J., Hoshino, H., Nishimura, D., Morita, K., Yoshida, N., Katada, N., Sano, H., Case report: Multiple cancers: Hepatocellular carcinoma and adenocarcinomas of the common bile duct and the gall-bladder in a woman with primary biliary cirrhosis (1996) J Gastroenterol Hepatol, 11, pp. 546-550; Hoso, M., Nakanuma, Y., Kawano, M., Oda, K., Tsuneyama, K., van de water, J., Gershiwin, M.E., Granulomatous cholangitis in chronic hepatitis C: A new diagnostic problem in liver pathology (1996) Pathol Int, 46, pp. 301-305; Mouelhi, L., Chaieb, M., Sfar, I., Debbeche, R., Trabelsi, S., Gorgi, Y., Najjar, T., Chronic viral C hepatitis associated with primary biliary cirrhosis. Report of two cases (2009) Rev Med Interne, 30, pp. 537-539; Ramos-Casals, M., Pares, A., Jara, L.J., Solans, R., Viñas, O., Vázquez, P., Sánchez-Tapias, Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: Description of 18 cases and review of the literature (2005) J Viral Hepat, 12, pp. 648-654. , HISPAMEC Study Group; Sung, J.L., Prevention of hepatitis B and C virus infection for prevention of cirrhosis and hepatocellular carcinoma (1997) J Gastroenterol Hepatol, 12, pp. S370-S376; Wang, J.T., Wang, T.H., Sheu, J.C., Tsai, S.J., Hsieh, Y.S., Lin, D.T., Wang, C.Y., Hepatitis C virus infection in volunteer blood donors in Taiwan. Evaluation by hepatitis C antibody assays and the polymerase chain reaction (1993) Arch Pathol Lab Med, 117, pp. 152-156; Nakamura, M., Yasunami, M., Kondo, H., Horie, H., Aiba, Y., Komori, A., Migita, K., Analysis of HLA-DRB1 polymorphisms in Japanese patients with primary biliary cirrhosis (PBC): The HLA-DRB1 polymorphism determines the relative risk of antinuclear antibodies for disease progression in PBC (2010) Hepatol Res, 40, pp. 494-504. , PBC Study Group in NHOSLJ; Gershwin, M.E., Selmi, C., Worman, H.J., Gold, E.B., Watnik, M., Utts, J., Lindor, K.D., Risk factors and comorbidities in primary biliary cirrhosis: A controlled interview based study of 1032 patients (2005) Hepatology, 42, pp. 1194-1202; Ala, A., Stanca, C.M., Bu-Ghanim, M., Ahmado, I., Branch, A.D., Schiano, T.D., Odin, J.A., Increased prevalence of primary biliary cirrhosis near superfund toxic waste sites (2006) Hepatology, 43, pp. 525-531; Ishibashi, H., Komori, A., Shimoda, S., Ambrosini, Y.M., Gershwin, M.E., Nakamura, M., Risk factors and prediction of long-term outcome in primary biliary cirrhosis (2011) Intern Med, 50, pp. 1-10; Cavazza, A., Caballería, L., Floreani, A., Farinati, F., Bruguera, M., Caroli, D., Parés, A., Incidence, Risk Factors, and Survival of Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Comparative Analysis from Two Centers (2009) Hepatology, 50, pp. 1162-1168; Macaron, C., Hanouneh, I.A., Zein, N.N., Incidence, Risk Factors, and Survival of Hepatocellular Carcinoma in Primary Biliary Cirrhosis (2010) Hepatology, 52, p. 2239. , author reply 2239-40; Michel, F., Toussirot, E., Wendling, D., Primary biliary cirrhosis and systemic lupus erythematosus. A new case report (1998) Rev Rhum Engl Ed, 65, pp. 504-507; Shizuma, T., Kuroda, H., A case of primary biliary cirrhosis which developed eight years after diagnosis of systemic lupus erythematosus (2011) Intern Med, 50, pp. 321-324; Watt, E.F., James, O.F., Jones, D.E., Patterns of autoimmunity in primary biliary cirrhosis patients and their families: A population-based cohort study (2004) QJM, 97, pp. 397-406; Fried, M.W., Shiffman, M.L., Reddy, K.R., Smith, C., Marinos, G., Gonçales Jr., F.L., Häussinger, D., Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection (2002) N Engl J Med, 26, pp. 975-982; Yoshikawa, M., Mimura, M., Shiroi, A., Kojima, H., Fukui, H., Sugimoto, Y., Mochi, T., Primary biliary cirrhosis exacerbated by a course of acute hepatitis C and subsequent interferon therapy (2000) Am J Gastroenterol, 95, pp. 2396-2397; Maeda, T., Onishi, S., Miura, T., Iwamura, S., Tomita, A., Saibara, T., Yamamoto, Y., Exacerbation of primary biliary cirrhosis during interferon-alpha 2b therapy for chronic active hepatitis C (1995) Dig Dis Sci, 40, pp. 1226-1230; D'Amico, E., Paroli, M., Fratelli, V., Palazzi, C., Barnaba, V., Callea, F., Consoli, G., Primary biliary cirrhosis induced by interferon-alpha therapy for hepatitis C virus infection (1995) Dig Dis Sci, 40, pp. 2113-2116; Lok, A.S., Gardiner, D.F., Lawitz, E., Martorell, C., Everson, G.T., Ghalib, R., Reindollar, R., Preliminary study of two antiviral agents for hepatitis C genotype 1 (2012) N Engl J Med, 366, pp. 216-224; Chung, R.T., A Watershed Moment in the Treatment of Hepatitis C (2012) N Engl J Med, 366, pp. 273-275

PY - 2013

Y1 - 2013

N2 - Background and aim. The aim of this study is to evaluate the role of hepatitis C virus (HCV) infection in patients with primary biliary cirrhosis (PBC). Material and methods. On the basis of a retrospective review of medical records, all patients consecutively diagnosed with PBC or HCV infection between 1999 and 2011 and who had a regular follow-up of at least 3 years were included in the study. Clinical characteristics, especially the severity of cirrhosis, were analyzed in PBC patients with HCV infection (PBC-HCV), PBC patients without HCV infection (PBC-only), and patients with only HCV infection (HCV-only). Results. A total of 76 patients with PBC, including 9 patients with HCV infection, were analyzed. Of the PBC-HCV patients, 7 (7/9, 77.8%) were women with a mean age of 55.11 ± 14.29 years. Age- and sex-matched PBC-only patients (n = 36) and HCV-only patients (n = 36) were used as control groups. In comparison to the PBC-only controls, PBC-HCV patients had a greater severity of cirrhosis based on Child-Pugh (p = 0.019) and Model for End-Stage Liver Disease (MELD) (p = 0.01) scores. However, no significant difference in the severity of cirrhosis was found between the PBC-HCV and HCV-only control patients (p = 0.94 in Child-Pugh scores; p = 0.64 in MELD scores). Conclusions. In PBC patients with concomitant HCV infection, aggressive management may be warranted in view of the associated more severe liver cirrhosis.

AB - Background and aim. The aim of this study is to evaluate the role of hepatitis C virus (HCV) infection in patients with primary biliary cirrhosis (PBC). Material and methods. On the basis of a retrospective review of medical records, all patients consecutively diagnosed with PBC or HCV infection between 1999 and 2011 and who had a regular follow-up of at least 3 years were included in the study. Clinical characteristics, especially the severity of cirrhosis, were analyzed in PBC patients with HCV infection (PBC-HCV), PBC patients without HCV infection (PBC-only), and patients with only HCV infection (HCV-only). Results. A total of 76 patients with PBC, including 9 patients with HCV infection, were analyzed. Of the PBC-HCV patients, 7 (7/9, 77.8%) were women with a mean age of 55.11 ± 14.29 years. Age- and sex-matched PBC-only patients (n = 36) and HCV-only patients (n = 36) were used as control groups. In comparison to the PBC-only controls, PBC-HCV patients had a greater severity of cirrhosis based on Child-Pugh (p = 0.019) and Model for End-Stage Liver Disease (MELD) (p = 0.01) scores. However, no significant difference in the severity of cirrhosis was found between the PBC-HCV and HCV-only control patients (p = 0.94 in Child-Pugh scores; p = 0.64 in MELD scores). Conclusions. In PBC patients with concomitant HCV infection, aggressive management may be warranted in view of the associated more severe liver cirrhosis.

KW - Child-Pugh score

KW - Cirrhosis

KW - MELD score

KW - alanine aminotransferase

KW - albumin

KW - aspartate aminotransferase

KW - bilirubin

KW - creatinine

KW - interferon

KW - ribavirin

KW - virus RNA

KW - adult

KW - age

KW - aged

KW - article

KW - ascites

KW - autoimmune disease

KW - bleeding

KW - Child Pugh score

KW - clinical article

KW - comorbidity

KW - controlled study

KW - death

KW - disease severity

KW - female

KW - follow up

KW - hepatitis C

KW - human

KW - international normalized ratio

KW - liver cell carcinoma

KW - liver cirrhosis

KW - male

KW - medical record review

KW - Model For End Stage Liver Disease Score

KW - neoplasm

KW - primary biliary cirrhosis

KW - survival rate

KW - virus load

KW - biliary cirrhosis

KW - case control study

KW - disease course

KW - middle aged

KW - prognosis

KW - retrospective study

KW - severity of illness index

KW - Adult

KW - Aged

KW - Case-Control Studies

KW - Disease Progression

KW - Female

KW - Hepatitis C

KW - Humans

KW - Liver Cirrhosis, Biliary

KW - Male

KW - Middle Aged

KW - Prognosis

KW - Retrospective Studies

KW - Severity of Illness Index

M3 - Article

SN - 1665-2681

VL - 12

SP - 78

EP - 84

JO - Annals of Hepatology

JF - Annals of Hepatology

IS - 1

ER -

Hepatitis C virus infection in patients with primary biliary cirrhosis

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this